Abstract 120P
Background
Cetuximab (Cet) plus chemotherapy (CT) has been approved as preferred first-line (1L) treatment for left-sided (LS) metastatic colorectal cancer (mCRC) with wild-type (wt) RAS/BRAF gene. However, it remains uncertain whether Cet is beneficial as maintenance therapy after 1L treatment. This study aimed to investigate the clinical outcomes for maintenance therapy in pts with LS RAS/BRAF wt mCRC who responded to 1L Cet plus CT.
Methods
We performed a retrospective review of pts with LS RAS/BRAF wt mCRC who had disease controlled (CR, PR or SD) after 6 cycles of Cet based induction therapy from JAN 2018 to JUN 2022 at HuNan Cancer Hospital. The 1L regimen consists of Cet plus mFOLFOX6 or FOLFIRI, based on pts selection, followed by maintenance therapy with Cetuximab with or without chemotherapy (cohort A) or chemotherapy alone (cohort B). Death data were obtained from the government's death registry. Kaplan-Meier methods were employed to describe overall survival (OS) and progression-free survival (PFS).
Results
A total of 125 pts were included in this study, with 72 (57.6%) in cohort A and 53 (42.4%) in cohort B. The median age was 58 years (range: 23-76), and 86 (68.8%) were male. The most common site of metastasis was the liver (90 patients, 72.0%). During a median follow-up of 32.6 m, the median OS from the start of 1L therapy was significantly longer in cohort A (46.4 m, 95% CI 40.1-NA) than in cohort B (31.1 m, 95% CI 27.6-38.0; p < 0.0001). Similarly, cohort A (14.2 m, 95% CI 12.4-17.0) had a significantly longer median PFS than cohort B (11.0 m, 95% CI 9.6-11.7; p=0.021). The Cox proportional hazards model, after adjusting for age, sex, primary tumor location, metastatic site, and whether the primary tumor and metastases were resected or not, showed that compared with cohort B, cohort A was associated with a statistically significant longer OS (HR 0.43, 95% CI 0.25-0.73) and a longer PFS, although the difference was not statistically significant (HR 0.70, 95% CI 0.44-1.12).
Conclusions
Maintenance therapy with Cet can significantly improve OS in pts with LS RAS/BRAF wt mCRC and lead to a clinically meaningful improvement in PFS, although the statistical difference was not reached.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract